US EditionWorld Health Organization recommends GLP-1 drugs as long-term obesity treatments
WHO advises GLP-1 drugs as part of comprehensive obesity care, noting fewer than 10% of eligible adults may access them by 2030 due to cost and supply constraints.
- On Monday, the World Health Organization recommended GLP-1 drugs as a tool to manage obesity in adults, publishing guidance in JAMA defining long-term use as six months or more.
- Regulatory approvals, including by the Food and Drug Administration, preceded the guidance drafted by a committee of obesity, pharmacology and public-health experts at the request of WHO member states amid debate in recent years.
- GLP-1 drugs work by mimicking a hormone that signals fullness and reduce appetite to help people lose weight, while more than 890 million adults worldwide are obese and obesity causes 3.7 million deaths annually.
- The recommendation is conditional, the WHO said, as benefits likely outweigh downsides but more long-term safety and efficacy data, plus lower prices, are needed to address access and pricing concerns.
- In the U.S., one in eight adults report currently taking a GLP-1 drug amid the societal shift in obesity framing and WHO urging public-health coordination.
80 Articles
80 Articles
WHO backs Ozempic-type drugs for treating obesity
WHO guidelines said GLP-1 medications such as Ozempic or Wegovy could be used by adults as part of a comprehensive approach to obesity treatment. Photo: Getty Images The World Health Organization has released its first guidelines on the Ozempic-type drugs, conditionally recommending their use for long-term treatment of obesity.
A range of medicines, called GLP-1, effective against overweight and diabetes, could help fight obesity, according to WHO.
GLP-1 drugs are "a powerful clinical tool" against obesity, said WHO on Monday, December 1. Globally, this disease affects more than a billion people. - Ozempic, Wegovy and Mounjaro: WHO recommends these treatments to fight obesity (Health and well-being).
WHO warns millions of people are being denied weight loss jabs as demand soars worldwide
The World Health Organization has just released its first-ever guidance on obesity medications like Wegovy, warning there's a massive problem with getting these drugs to people who need them. Less than one in ten people who could benefit from these injections can actually access them, despite more than a billion people worldwide now living with obesity.The WHO is calling for much fairer and broader access to GLP-1 medications, which are already …
Coverage Details
Bias Distribution
- 45% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
